SCHEMBL17245376

SCHEMBL17245376

O=C(O)c1cnc2ccc(Br)cc2c1N[C@@H]1CCCOC1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.44
ATM Q13315 5/20 0.43
KCNH2 Q12809 4/20 0.43
ATR Q13535 3/20 0.43
CD38 P28907 1/20 0.43
RXFP1 Q9HBX9 3/20 0.41
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.39
MELK Q14680 3/20 0.39
MAPK1 P28482 1/20 0.39
AURKA O14965 1/20 0.39
RPS6KB1 P23443 1/20 0.39
EGFR P00533 1/20 0.38
ERBB2 P04626 1/20 0.38
GAA P10253 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MAPK8 P45983 1/20 0.38
MAPK9 P45984 1/20 0.38
IRAK4 Q9NWZ3 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19329163 1.00 PDE4B (0.44) PDE4BATMKCNH2ATRCD38
SCHEMBL17272486 1.00 PDE4B (0.44) PDE4BATMKCNH2ATRCD38
SCHEMBL18327212 0.94 ATM (0.48) PDE4BATMKCNH2ATRCD38
SCHEMBL17241454 0.94 ATM (0.48) PDE4BATMKCNH2ATRCD38
SCHEMBL17246343 0.94 ATM (0.48) PDE4BATMKCNH2ATRCD38
SCHEMBL18843698 0.89 TSHR (0.44) PDE4BATMKCNH2ATRRXFP1
SCHEMBL17272549 0.88 PDE4B (0.52) PDE4BATMKCNH2ATRTSHR
SCHEMBL18843793 0.88 PDE4B (0.54) PDE4BATMKCNH2ATRTSHR
SCHEMBL17241414 0.87 KCNH2 (0.55) PDE4BATMKCNH2ATRRXFP1
SCHEMBL18844648 0.86 RXFP1 (0.59) PDE4BRXFP1HTTMAPK1AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190185468-A1 Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer ASTRAZENECA UK LIMITED (GB) 2019-06-20 US disclosed
US-20190185468-A1 Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer ASTRAZENECA UK LIMITED (GB) 2019-06-20 US disclosed
US-10189834-B2 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer ASTRAZENECA AB (SE) 2019-01-29 US disclosed
US-10189834-B2 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer ASTRAZENECA AB (SE) 2019-01-29 US disclosed
US-20180318287-A1 Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer ASTRAZENECA AB (SE) 2018-11-08 US disclosed
US-20180280377-A1 Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer ASTRAZENECA UK LIMITED (GB) 2018-10-04 US disclosed
US-20180134699-A1 Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer ASTRAZENECA UK LIMITED (GB) 2018-05-17 US disclosed
US-20180134699-A1 Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer ASTRAZENECA UK LIMITED (GB) 2018-05-17 US disclosed
US-20180134699-A1 Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer ASTRAZENECA UK LIMITED (GB) 2018-05-17 US disclosed
EP-3140303-B1 IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2018-03-28 EP disclosed
US-20160368920-A1 Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer ASTRAZENECA AB (SE) 2016-12-22 US disclosed
US-20160368920-A1 Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer ASTRAZENECA AB (SE) 2016-12-22 US disclosed
US-20160368920-A1 Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer ASTRAZENECA AB (SE) 2016-12-22 US disclosed
US-9428503-B2 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating Cancer ASTRAZENECA AB (SE) 2016-08-30 US disclosed
US-9428503-B2 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating Cancer ASTRAZENECA AB (SE) 2016-08-30 US disclosed
US-9428503-B2 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating Cancer ASTRAZENECA AB (SE) 2016-08-30 US disclosed
US-20150336952-A1 Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer ASTRAZENECA AB (SE) 2015-11-26 US disclosed
US-20150336952-A1 Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer ASTRAZENECA AB (SE) 2015-11-26 US disclosed
US-20150336952-A1 Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer ASTRAZENECA AB (SE) 2015-11-26 US disclosed
WO-2015170081-A1 IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2015-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134699-A1 Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer ATM, CHEK2, CHEK1 PDE4B 549/4885ATM 1/4885KCNH2 1895/4885
US-20190185468-A1 Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer ATM, CHEK2, CHEK1 PDE4B 549/4885ATM 1/4885KCNH2 1895/4885
US-20180280377-A1 Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer ATM, BRCA1, CHEK2 PDE4B 440/4885ATM 1/4885KCNH2 2759/4885
US-20180318287-A1 Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer ATM, BRCA1, CHEK2 PDE4B 272/4885ATM 1/4885KCNH2 2805/4885
US-20160368920-A1 Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer ATM, CHEK2, CHEK1 PDE4B 549/4885ATM 1/4885KCNH2 1895/4885
US-20150336952-A1 Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer ATM, CHEK2, CHEK1 PDE4B 549/4885ATM 1/4885KCNH2 1895/4885
US-10189834-B2 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer ATM, CHEK2, CHEK1 PDE4B 549/4885ATM 1/4885KCNH2 1895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.